JavaScript NENÍ povolen !

Prosím povolte JavaScript.

Článek

PubMed

Záznam pochází z PubMed

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]

Iro, Mildred A
Autor Iro, Mildred A Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: mildred.iro@paediatrics.ox.ac.uk
Snape, Matthew D
Autor Snape, Matthew D Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK
Voysey, Merryn
Autor Voysey, Merryn Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK
Jawad, Sena
Autor Jawad, Sena Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK
Finn, Adam
Autor Finn, Adam Bristol Children's Vaccine Centre, University of Bristol, Bristol, UK
Heath, Paul T
Autor Heath, Paul T St Georges Vaccine Institute, St George's, University of London, London, UK
Bona, Gianni
Autor Bona, Gianni Azienda Ospedaliero-Universitaria Maggiore della Carità, Clinica Pediatrica, Novara, Italy
Esposito, Susanna
Autor Esposito, Susanna Pediatric Highly Intensive Care Unit, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Diez-Domingo, Javier
Autor Diez-Domingo, Javier Vaccine Research Area, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain
Prymula, Roman
Autor Prymula, Roman Charles University Prague, School of Medicine Hradec Kralove, Czech Republic
Odueyungbo, Adefowope
Autor Odueyungbo, Adefowope Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA
Toneatto, Daniela
Autor Toneatto, Daniela GSK Vaccines S.r.l., Siena, Italy
Dull, Peter
Autor Dull, Peter Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA
Pollard, Andrew J
Autor Pollard, Andrew J Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK
European Men B Vaccine Study Group
Autor European Men B Vaccine Study Group

Vaccine. 2017 May 31 ; 35 (24) : 3279. [epub] 20170505

ISSN 1873-2518 | 0264-410X
Zdroj

Status PubMed-not-MEDLINE Jazyk angličtina Země Nizozemsko Médium print-electronic

Typ dokumentu časopisecké články, tisková chyba

Perzistentní odkaz https://www.medvik.cz/link/pmid28483197

PubMed 28483197
DOI 10.1016/j.vaccine.2017.04.081
PII: S0264-410X(17)30582-0
Knihovny.cz E-zdroje

Azienda Ospedaliero Universitaria Maggiore della Carità Clinica Pediatrica Novara Italy

Bristol Children's Vaccine Centre University of Bristol Bristol UK

Charles University Prague School of Medicine Hradec Kralove Czech Republic

GSK Vaccines S r l Siena Italy

Novartis Vaccines and Diagnostics Inc Cambridge MA USA

Nuffield Department of Primary Health Care Health Sciences University of Oxford Oxford UK

Oxford Vaccine Group Department of Paediatrics University of Oxford and the NIHR Oxford Biomedical Research Centre Oxford UK

Oxford Vaccine Group Department of Paediatrics University of Oxford and the NIHR Oxford Biomedical Research Centre Oxford UK; Nuffield Department of Primary Health Care Health Sciences University of Oxford Oxford UK

Pediatric Highly Intensive Care Unit Università degli Studi di Milano Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy

St Georges Vaccine Institute St George's University of London London UK

Vaccine Research Area Fundación para el Fomento de la Investigación Sanitaria y Biomédica Valencia Spain

Erratum pro

Vaccine. 2017 Jan 5;35(2):395-402. doi: 10.1016/j.vaccine.2016.11.009. PubMed

Citace poskytuje Crossref.org

Najít záznam

v BMČ

Citační ukazatele

Pouze přihlášení uživatelé

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]

Najít záznam

Citační ukazatele

Možnosti archivace